AstraZeneca saw revenues and product sales fall over the course of 2017. Total revenues declined 2 percent to $22.46 billion and product sales fell 5 percent to $20.15 billion.

Pharma giant AstraZeneca has seen a fourfold increase in research productivity following a narrowing of disease focus and cuts in laboratory and staff over the past seven years, Reuters reported.

Forty Seven Inc., a clinical-stage company focused on developing the next generation of transformational immuno-oncology treatments to enable a patient’s immune system to defeat their cancer, announced an agreement with Merck KGaA to conduct a Phase 1b clinical trial combining Hu5F9-G4 with avelumab in patients with ovarian cancer.

Merck KGaA and Pfizer Inc. announced that the U.S. FDA granted Breakthrough Therapy Designation for avelumab in combination with Inlyta (axitinib) treatment-naïve patients with advanced renal cell carcinoma.

Merck KGaA struck a deal worth up to €1 billion to acquire five bispecific immuno-oncology antibodies from F-star Alpha.

As AstraZeneca continues to move its operations to new headquarters in Cambridge, England, the company quietly pushed back its timeline for a late-stage lung cancer trial.

Three years after Pfizer’s failed bid for AstraZeneca, the British drugmaker aims to prove that its cancer immunotherapy can deliver on bold sales forecasts made during that takeover battle.

Novartis is making progress in its bid to catch rivals developing drugs that harness the immune system to fight cancer, one of its top research scientists told Reuters.

AstraZeneca canceled its combination of PD-L1 durvalumab and CTLA-4 medication tremelimumab in pancreatic ductal carcinoma.

Merck & Co. has pulled ahead of rivals in the race to combine immunotherapy with other drugs as a treatment for lung cancer,.